1,2-Beta-methylene-4-substituted androstene-3,17-dione derivatives and process for their preparation
    5.
    发明公开
    1,2-Beta-methylene-4-substituted androstene-3,17-dione derivatives and process for their preparation 失效
    1,2-β-亚甲基-4-取代基 - 雄甾-3,17-二酮衍生物和Verfahren zu ihrer Herstellung。

    公开(公告)号:EP0265119A1

    公开(公告)日:1988-04-27

    申请号:EP87308891.8

    申请日:1987-10-07

    IPC分类号: C07J53/00 A61K31/565

    摘要: The invention relates to new aromatase inhibitor agents having the general formula (I)
    wherein R 1 is hydrogen or a group = CHR 3 wherein R 3 is hydrogen or C 1 -C 6 alkyl; the symbol ----- indicates - the presence of a single or double bond in such a way that, when R 1 is hydrogen, (a) is single bond and (b) is either single or double bond, while, when R 1 is a group = CHR 3 as defined above, (a) is double bond and (b) is single bond; R 2 is hydrogen or fluorine; and R is



    1) a group -OR 4 wherein R 4 is
    a) hydrogen;
    b) C 1 -C 6 alkyl;
    c) a phenyl or benzyl group, each unsubstituted or ring-substituted by one or more substituents chosen from C 1 -C 4 alkl, halogen, trifluoromethyl, nitro, amino, hydroxy and C 1 -C 4 alkoxy;
    d) a group - COR 5 wherein R 5 is

    (i) a C 1 -C 22 saturated or C 2 -C 22 unsaturated aliphatic hydrocarbon radical;
    (ii) a C 4 -C 7 monocycloalkyl group; or
    (iii) a phenyl or benzyl group, each unsubstituted or ring substituted as reported above; or

    e) a hydroxy protecting group;

    2) a group - SR 6 wherein R 6 either has one of the meanings (a) to (d) indicated above for R 4 or is a group -SR 7 wherein, R 7 is

    (iv) C 1 -C 6 alkyl;
    (v) a phenyl or benzyl group, each unsubstituted or ring-substituted as reported above; or
    (vi) a steroidic residue of formula
    wherein R 1 , R 2 , (a), (b) and the symbol --- are as defined above;

    3) the group -N 3 ; or
    4). a group
    wherein each of R s and R 9 , independently, is hydrogen or C 1 -C 6 alkyl, and the pharmaceutically acceptable salts thereof, which are useful in therapy, in particular, as anti-cancer agents.

    摘要翻译: 本发明涉及具有通式(I)的新的芳香酶抑制剂,其中R 1是氢或基团= CHR 3,其中R 3是氢或C 1 -C 6烷基; 符号-----表示存在单键或双键,当R1为氢时,(a)为单键,(b)为单键或双键,而当R1为 基团= CHR 3,(a)为双键,(b)为单键; R2是氢或氟; 和R为1)基团-OR4,其中R4为a)氢; b)C 1 -C 6烷基; c)苯基或苄基,各自未被取代或被一个或多个选自C 1 -C 4烷基,卤素,三氟甲基,硝基,氨基,羟基和C 1 -C 4烷氧基的取代基取代或环取代; d)基团-OR 5,其中R 5是(i)C 1 -C 22饱和或C 2 -C 22不饱和脂族烃基; (ⅱ)C 4 -C 7单环烷基; 或(iii)苯基或苄基,每个未取代或环取代如上所述; 或e)羟基保护基; 2)基团-SR 6,其中R 6具有上面对R 4表示的含义(a)至(d)中的一个或者是-SR 7基团,其中R 7是(ⅳ)C 1 -C 6烷基; (v)苯基或苄基,如上所述,各自未取代或环取代; 或(vi)式的类固醇残基,其中R 1,R 2,(a),(b)和符号如上所定义; 3)组-N3; 或4)一种,其中R8和R9各自独立地是氢或C1-C6烷基,及其药学上可接受的盐,其可用于治疗,特别是作为抗癌剂。

    1,2Beta-Methylen-4-androsten-und 4,6-androstadien-3,17-dione
    6.
    发明公开
    1,2Beta-Methylen-4-androsten-und 4,6-androstadien-3,17-dione 失效
    1,2β-甲基-4-雄甾-4,6-雄甾二烯-3,17-二酮。

    公开(公告)号:EP0164699A2

    公开(公告)日:1985-12-18

    申请号:EP85107029.2

    申请日:1985-06-07

    IPC分类号: C07J53/00 A61K31/565

    CPC分类号: C07J53/005

    摘要: 1,2ß-Methylen-4-androsten- und 4,6-androstadien-3,17-dione der allgemeinen Formel I
    worin die gestrichelte Linie das Fehlen oder Vorhandensein einer zusätzlichen Doppelbindung in 6,7-Stellung bedeutet.
    Die neuen Verbindungen der allgemeinen Formel I sind als Inhibitoren der Östrogenbiosynthese zur Fertilitätskon - trolle und zur Behandlung von Krankheiten geeignet, die durch Östrogene hervorgerufen werden.

    摘要翻译: 1,2β-亚甲基-4-雄甾烯-4,6-己二烯-3,17-二酮,其中虚线表示在位置6处不存在或存在另外的双键, 7,适合作为雌激素生物合成抑制剂,用于生育控制和治疗由雌激素引起的疾病。